intranas
administ
liveattenu
influenza
viru
laiv
vaccin
provid
signific
protect
heterolog
influenza
viru
iav
challeng
howev
laiv
administr
modifi
bacteri
microbiota
upper
respiratori
tract
includ
alter
speci
caus
pneumonia
sought
evalu
effect
bordetella
bronchiseptica
colon
laiv
immunogen
efficaci
swine
impact
laiv
iav
challeng
b
bronchiseptica
colon
diseas
laiv
immunogen
significantli
impact
b
bronchiseptica
colon
protect
efficaci
heterolog
iav
challeng
upper
respiratori
tract
impair
titer
iav
nose
trachea
pig
receiv
laiv
significantli
reduc
compar
nonvaccin
challeng
control
regardless
b
bronchiseptica
infect
pneumonia
score
higher
pig
colon
b
bronchiseptica
challeng
iav
regardless
laiv
vaccin
statu
laiv
vaccin
provid
signific
protect
heterolog
iav
challeng
protect
steril
iav
replic
respiratori
tract
laiv
vaccin
pig
interact
iav
b
bronchiseptica
host
led
develop
acutetyp
b
bronchiseptica
lesion
lung
thu
data
present
negat
efficaci
laiv
vaccin
instead
indic
control
b
bronchiseptica
colon
swine
could
limit
neg
interact
iav
bordetella
swine
health
influenza
viru
iav
major
anim
public
health
concern
given
zoonot
natur
iav
natur
host
iav
research
iav
swine
relev
human
anim
medicin
iav
segment
negativesens
singlestrand
rna
viru
surfac
glycoprotein
hemaggluttinin
ha
neuraminidas
na
use
type
iav
current
virus
circul
pig
unit
state
larg
number
iav
genet
antigen
variant
cocircul
continu
antigen
drift
shift
circul
virus
made
control
iav
swine
difficult
liveattenu
influenza
viru
laiv
vaccin
swine
shown
provid
crossprotect
heterolog
iav
subtyp
partial
protect
differ
subtyp
review
sandbult
et
al
laiv
licens
use
human
recent
approv
use
swine
numer
experiment
studi
document
improv
efficaci
laiv
inactiv
vaccin
sever
laiv
vaccin
use
swine
develop
differ
attenu
mechan
similar
human
intranas
laiv
vaccin
pig
induc
product
iavspecif
mucos
iga
littl
peripher
iavspecif
igg
induct
immun
respiratori
tract
shown
mechan
laiv
vaccin
provid
signific
crossprotect
heterolog
strain
iav
limit
viral
replic
throughout
respiratori
tract
review
rose
et
al
bordetella
bronchiseptica
colon
respiratori
tract
larg
number
mammal
includ
mice
rabbit
dog
pig
among
other
respiratori
diseas
associ
b
bronchiseptica
cover
wide
spectrum
includ
kennel
cough
dog
atroph
rhiniti
pig
human
b
pertussi
infect
lead
whoop
cough
though
colon
without
clinic
present
document
similarli
b
bronchiseptica
exposur
pig
result
chronic
asymptomat
colon
respiratori
tract
believ
ubiquit
swine
product
system
coinfect
iav
coronaviru
b
bronchiseptica
pig
caus
exacerb
pulmonari
diseas
indic
neg
impact
b
bronchiseptica
colon
viral
infect
bordetella
speci
encod
number
virul
factor
includ
tracheal
cytotoxin
dermonecrot
toxin
lipopolysaccharid
type
iii
secret
system
gene
locu
control
express
mani
virul
factor
includ
type
iii
secret
system
highli
investig
factor
alter
express
virul
gene
vivo
complet
understood
past
decad
complex
interact
mucos
surfac
colon
microbiota
recogn
import
modul
health
diseas
state
review
esposito
principi
commens
microbiota
upper
respiratori
tract
includ
bacteri
speci
colon
alon
lead
clinic
diseas
upon
stress
event
ie
viral
infect
immunosuppress
bacteria
play
major
role
diseas
pathogenesi
often
refer
pathobiont
administr
laiv
vaccin
induc
chang
nasal
microbiota
gene
express
nasal
epithelium
addit
laiv
administr
alter
colon
dynam
import
bacteri
pathogen
given
ubiquit
natur
b
bronchiseptica
swine
document
increas
diseas
follow
b
bronchiseptica
iav
coinfect
perform
studi
determin
b
bronchiseptica
colon
prior
laiv
vaccin
alter
laiv
immunogen
efficaci
heterolog
iav
challeng
dynam
b
bronchiseptica
colon
b
bronchiseptica
strain
virul
phase
swine
isol
initi
cultur
herd
atroph
rhiniti
use
extens
group
studi
b
bronchiseptica
inoculum
prepar
previous
describ
pig
inocul
intranas
ml
mlnostril
final
inoculum
confirm
log
cfuml
laiv
vaccin
prepar
use
previous
describ
anim
studi
conduct
accord
nation
anim
diseas
center
institut
anim
care
use
committe
pregnant
sow
transfer
nation
anim
diseas
center
nadc
approxim
week
prior
farrow
due
date
herd
neg
iavspecif
antibodi
porcin
reproduct
respiratori
syndrom
viru
piglet
earli
wean
sow
approxim
day
age
reduc
vertic
transmiss
bacteri
respiratori
pathogen
colon
sow
piglet
piglet
transfer
individu
isol
room
base
treatment
piglet
litter
repres
treatment
group
tabl
nasal
swab
collect
piglet
prior
inocul
neither
iav
b
bronchiseptica
isol
week
age
piglet
group
inocul
b
bronchiseptica
bb
intranas
rout
consid
experi
seven
day
later
piglet
week
age
anim
group
inocul
laiv
rout
consid
day
studi
second
dose
laiv
administ
studi
day
week
postlaiv
prime
nasal
swab
collect
bb
inocul
day
immedi
prior
laiv
administr
day
evalu
bb
nasal
colon
follow
laiv
vaccin
nasal
wash
collect
day
immedi
prior
laiv
boost
week
postboost
evalu
bb
nasal
colon
iavspecif
mucos
antibodi
titer
blood
collect
serum
isol
evalu
antibodi
titer
day
pig
group
challeng
heterolog
iav
rout
nasal
swab
collect
everi
day
day
follow
iav
challeng
evalu
iav
titer
nose
day
postinfect
dpi
pig
euthan
lethal
dose
pentobarbit
necropsi
perform
necropsi
gross
lung
lesion
score
determin
base
percentag
lung
lobe
affect
percentag
total
lung
volum
lobe
repres
calcul
initi
describ
postmortem
sampl
collect
includ
nasal
swab
trachea
wash
bronchoalveolar
lung
lavag
fluid
balf
nasal
swab
nasal
wash
trachea
wash
sampl
collect
previous
describ
minor
modif
briefli
nasal
swab
collect
ml
minim
essenti
media
mem
trachea
wash
perform
ml
mem
balf
collect
lavag
lobe
ml
mem
recov
much
possibl
approxim
ml
section
lung
collect
microscop
evalu
lung
tissu
fix
neutral
buffer
formalin
h
process
stain
hematoxylin
eosin
use
routin
procedur
nasal
wash
sampl
collect
day
iav
challeng
day
use
indirect
wholeviru
enzymelink
immunosorb
assay
elisa
previous
describ
briefli
concentr
vaccin
viru
challeng
viru
use
antigen
ml
per
well
nasal
wash
use
sampl
assay
iavspecif
iga
detect
horseradish
peroxidaselabel
antiswin
iga
dilut
clone
bethyl
laboratori
iavspecif
iga
endpoint
titer
determin
titrat
sampl
twofold
duplic
perform
elisa
optic
densiti
od
data
model
nonlinear
function
log
dilut
use
graphpad
prism
graphpad
softwar
inc
la
jolla
ca
log
agonist
vs
responsevari
slope
fourparamet
logist
model
endpoint
interpol
use
averag
od
nasal
wash
sampl
nonvaccin
control
cutoff
number
colonyform
unit
cfu
b
bronchiseptica
per
ml
swab
fluid
nasal
wash
tracheal
wash
balf
determin
previous
describ
briefli
sampl
serial
dilut
phosphatebuff
salin
pb
plate
blood
agar
trachea
wash
balf
blood
agar
supplement
ugml
amikacin
ugml
vancomycin
ugml
amphotericin
b
nasal
swab
nasal
wash
aliquot
balf
also
plate
brainheart
infus
agar
supplement
nad
wv
hors
serum
rule
aerob
bacteri
infect
b
bronchiseptica
respect
group
determin
viral
load
nasal
swab
trachea
wash
balf
thaw
filter
um
syring
filter
fluid
use
previous
describ
viru
isol
titrat
immunohistochemistri
stain
use
evalu
number
tcid
ml
sampl
calcul
method
reed
muench
sampl
neg
viru
isol
assign
valu
zero
sampl
neg
viru
titrat
posit
viru
isol
assign
valu
log
tcid
ml
balf
collect
necropsi
dpi
aliquot
centrifug
x
g
min
cellfre
supernat
collect
use
evalu
cytokin
level
lung
amount
cellfre
lung
lavag
determin
singleplex
kingfish
biotech
multiplex
cytokin
elisa
aushon
biosystem
respect
previous
describ
twofactor
repeat
measur
mix
effect
model
analysi
log
cfu
differ
treatment
group
bblaiv
bbnv
dpi
repeat
measur
factor
use
pig
subject
use
evalu
statist
differ
bb
nasal
colon
sa
weight
regress
equat
log
tcid
function
dpi
bblaivch
bbnvch
laivch
nvch
group
use
mean
log
tcid
valu
standard
weight
confid
limit
use
statist
comparison
nasal
shed
sa
oneway
anova
tukey
posttest
use
evalu
differ
lung
lesion
respiratori
tract
bb
colon
respiratori
tract
iav
burden
graphpad
prism
unpair
student
ttest
use
analysi
iavspecif
iga
level
kruskalw
test
dunn
multipl
comparison
posttest
use
determin
statist
differ
lung
cytokin
level
graphpad
prism
given
laiv
vaccin
deliv
rout
effect
laiv
administr
b
bronchiseptica
nasal
colon
assess
variou
time
point
follow
laiv
vaccin
time
initi
dose
laiv
administ
week
b
bronchiseptica
inocul
signific
differ
b
bronchiseptica
colon
treatment
group
p
figur
numer
trend
differ
group
day
follow
initi
dose
laiv
statist
differ
tabl
pig
group
includ
bbnv
group
n
group
pig
use
bblaiv
group
n
data
report
number
cfu
per
ml
nasal
swab
day
nasal
wash
day
signific
differ
p
bb
cfu
note
asterisk
group
p
pig
laiv
group
boost
day
signific
differ
b
bronchiseptica
colon
treatment
group
time
laiv
administr
day
week
follow
administr
booster
dose
day
p
day
rel
laiv
administr
signific
differ
p
b
bronchiseptica
cfu
nasal
wash
bblaiv
bbnv
treatment
group
though
averag
limit
less
log
differ
vs
log
cfu
semml
respect
macroscop
pneumonia
strict
control
group
noninfect
nonvaccin
minim
macroscop
lesion
detect
pig
inocul
b
bronchiseptica
bbnvnch
group
averag
lung
affect
figur
signific
increas
percentag
gross
pneumonia
nvch
group
compar
control
group
though
percentag
pig
group
present
lesion
differ
vs
respect
also
signific
differ
nvch
laivch
group
p
averag
percentag
lung
affect
lesion
nvch
group
compar
laivch
group
increas
percentag
lung
affect
bbnvch
bblaivch
group
compar
strict
control
group
p
bbnvch
bblaivch
group
p
bronchiseptica
colon
pig
regardless
laiv
vaccin
statu
group
pig
inocul
b
bronchiseptica
bb
laiv
day
subsequ
challeng
ch
heterolog
iav
describ
materi
method
nonvaccin
nv
group
nvnonchalleng
nvnch
control
group
includ
control
day
postinfect
percentag
lung
affect
macroscop
lesion
determin
report
percent
pneumonia
calcul
describ
materi
method
dot
repres
score
pig
respect
group
averag
indic
bar
red
data
point
indic
score
sampl
lung
section
use
figur
data
analyz
use
oneway
anova
tukey
posttest
graphpad
prism
group
connect
line
significantli
differ
p
microscop
lesion
either
present
minim
limit
mild
interstiti
thicken
strict
control
group
nvnch
figur
well
pig
inocul
b
bronchiseptica
alon
bbnvnch
two
bbnvnch
pig
microscop
chang
lesion
consist
chronic
b
bronchiseptica
pneumonia
character
moder
thicken
alveolar
septa
fibrin
collagen
type
ii
pneumocyt
hyperplasia
alveolar
space
variabl
fill
macrophag
figur
pig
inocul
iav
alon
nvch
mild
lesion
consist
iav
infect
character
primarili
suppur
bronchiti
bronchiol
epitheli
necrosi
peribronchiolar
lymphocyt
infiltr
figur
presenc
sever
interstiti
pneumonia
minim
mild
nvch
group
iavassoci
lesion
diminish
vaccin
group
laivch
compar
nonvaccin
group
nvch
particular
suppur
bronchiti
bronchiol
epitheli
necrosi
reduc
howev
peribronchiolar
lymphocyt
infiltr
bronchu
associ
lymphoid
tissu
balt
hyperplasia
major
laivch
pig
figur
pig
infect
b
bronchiseptica
subsequ
challeng
iav
bbnvch
microscop
lesion
consist
iav
infect
well
acut
chronic
b
bronchiseptica
pneumonia
figur
influenza
lesion
includ
suppur
bronchiti
bronchiol
epitheli
necrosi
submucos
lymphohistiocyt
inflamm
well
peribronchiolar
lymphocyt
infiltr
howev
suppur
bronchiti
bronchiol
tend
sever
observ
pig
infect
iav
alon
furthermor
alveoli
variabl
fill
neutrophil
macrophag
area
alveolar
epitheli
necrosi
hemorrhag
type
ii
pneumocyt
hyperplasia
consist
acut
bordetellosi
addit
section
bbnvch
pig
area
consist
chronic
bordetellosi
character
interstiti
figur
b
bronchiseptica
respiratori
tract
colon
affect
iav
challeng
regardless
laiv
vaccin
statu
group
pig
inocul
b
bronchiseptica
bb
laiv
day
subsequ
challeng
ch
heterolog
iav
describ
materi
method
day
postinfect
nasal
swab
trachea
wash
lung
lavag
collect
pig
necropsi
bb
enumer
determin
iav
effect
bb
colon
respiratori
tract
dot
repres
singl
anim
respect
treatment
group
averag
sem
indic
dot
line
repres
limit
detect
data
analyz
use
oneway
anova
tukey
posttest
graphpad
prism
signific
differ
group
p
pneumonia
consist
alveolar
septal
thicken
mononuclear
cell
well
fibrin
collagen
figur
final
note
laivch
group
vaccin
pig
infect
bordetella
challeng
iav
bblaivch
diminish
bronchial
bronchiolar
epitheli
necrosi
howev
pig
lesion
consist
acut
chronic
bordetella
pneumonia
includ
acut
lesion
consist
alveoli
bronchiol
variabl
fill
neutrophil
andor
macrophag
alveoli
area
epitheli
necrosi
hemorrhag
type
ii
pneumocyt
hyperplasia
figur
section
pig
bblaivch
group
also
contain
chronic
lesion
interstiti
pneumonia
consist
alveolar
septal
thicken
mononuclear
cell
well
fibrin
collagen
consist
chronic
b
bronchiseptica
infect
determin
b
bronchiseptica
colon
level
respiratori
tract
alter
follow
iav
challeng
amount
b
bronchiseptica
nasal
swab
trachea
wash
lung
lavag
collect
pig
necropsi
determin
b
bronchiseptica
recov
nasal
swab
collect
dpi
pig
inocul
b
bronchiseptica
signific
differ
colon
level
group
p
figur
b
bronchiseptica
colon
trachea
lung
also
similar
group
signific
differ
note
p
figur
b
bronchiseptica
recov
sampl
collect
pig
inocul
b
bronchiseptica
data
shown
experiment
intranas
laiv
vaccin
shown
provid
signific
protect
heterolog
iav
replic
follow
challeng
includ
protect
challeng
viru
use
studi
determin
b
bronchiseptica
colon
alter
laiv
vaccin
efficaci
iav
titer
respiratori
tract
follow
heterolog
iav
challeng
determin
nasal
swab
collect
day
iav
challeng
daili
dpi
tabl
report
number
pig
group
shed
viru
figur
report
titer
anim
averag
titer
log
tcid
ml
indic
group
indic
dpi
one
day
intranas
iav
challeng
nvch
pig
shed
viru
averag
iav
titer
log
tcid
ml
significantli
increas
laivch
group
p
signific
differ
iav
titer
nasal
swab
nvch
laivch
group
note
day
well
figur
signific
differ
iav
titer
nasal
swab
bbnvch
bblaivch
group
everi
time
point
well
p
indic
b
bronchiseptica
colon
complet
inhibit
efficaci
laiv
vaccin
plot
nasal
swab
iav
titer
individu
anim
figur
indic
rang
amount
viru
shed
pig
respect
group
thu
averag
nasal
swab
titer
significantli
differ
group
broad
rang
shed
titer
within
group
iav
nasal
shed
greater
bbnvch
group
compar
nvch
group
dpi
differ
dpi
dpi
titer
greater
nvch
group
figur
similarli
iav
shed
greater
bblaivch
group
compar
laivch
day
differ
day
dpi
titer
greater
laivch
pig
figur
howev
dpi
averag
amount
viru
shed
laiv
vaccin
group
regardless
b
bronchiseptica
statu
less
log
tcid
ml
indic
laiv
vaccin
efficaci
pig
bblaivch
group
shed
viru
day
pig
laivch
group
shed
respect
dpi
signific
differ
percentag
pig
bblaivch
laivch
group
shed
viru
tabl
result
indic
b
bronchiseptica
infect
regardless
laiv
vaccin
statu
affect
iav
replic
nasal
caviti
iav
titer
lower
respiratori
tract
dpi
also
evalu
signific
differ
p
titer
iav
trachea
wash
laivch
pig
compar
bblaivch
pig
specif
iav
isol
trachea
wash
pig
laivch
group
wherea
iav
isol
trachea
wash
pig
bblaivch
group
signific
differ
titer
two
treatment
group
p
figur
howev
b
bronchiseptica
complet
interfer
laiv
efficaci
titer
iav
trachea
wash
bblaivch
group
significantli
reduc
compar
bbnvch
group
p
expect
averag
titer
iav
trachea
lung
lavag
pig
laivch
group
significantli
reduc
compar
nvch
group
indic
protect
heterolog
viru
replic
follow
laiv
vaccin
figur
c
protect
heterolog
viru
replic
also
note
bblaivch
group
iav
isol
lung
lavag
pig
group
determin
b
bronchiseptica
colon
inhibit
laiv
immunogen
iga
titer
iav
nasal
wash
sampl
collect
immedi
prior
iav
challeng
determin
figur
reciproc
endpoint
titer
iga
vaccin
viru
challeng
viru
determin
use
whole
viru
elisa
signific
differ
nasal
wash
iga
titer
either
viru
two
vaccin
group
p
indic
laiv
immunogen
nasal
caviti
neg
impact
b
bronchiseptica
colon
pearson
correl
test
evalu
nw
iavspecif
iga
reciproc
titer
report
figur
iav
nasal
swab
titer
averag
day
day
report
figur
perform
statist
correl
data
data
shown
determin
lung
lesion
sever
associ
inflammatori
cytokin
respons
level
sever
cytokin
measur
lung
lavag
collect
necropsi
figur
antivir
cytokin
increas
lavag
nonvaccin
pig
challeng
iav
regardless
b
bronchiseptica
colon
p
also
observ
p
specif
cytokin
level
increas
nvch
bbnvch
pig
respect
vaccin
group
laivch
bblaivch
test
cytokin
level
significantli
increas
nonvaccin
group
colon
bb
challeng
iav
nonvaccin
iav
infect
pig
suggest
bb
coinfect
led
enhanc
product
level
increas
lung
bbnvnch
pig
control
pig
howev
level
bbnvnch
pig
significantli
differ
level
b
bronchiseptica
colon
group
bbnvnch
bblaivch
signific
increas
level
lung
follow
iav
challeng
nonvaccin
pig
level
significantli
differ
vaccin
challeng
pig
regardless
bb
statu
collect
data
indic
cytokin
level
increas
primarili
pig
challeng
iav
previous
vaccin
fisher
exact
test
p
intranas
deliv
laiv
vaccin
shown
experiment
provid
signific
crossprotect
heterolog
iav
pig
major
experiment
challeng
studi
swine
laiv
use
pig
procur
high
health
statu
herd
free
mani
bacteria
pathogen
condit
ie
pathobiont
associ
secondari
diseas
commerci
set
bacteria
includ
limit
bordetella
mycoplasma
haemophilu
streptococcu
also
associ
respiratori
diseas
complex
multifactori
diseas
infecti
agent
environ
manag
practic
play
role
suscept
much
like
b
pertussi
human
b
bronchiseptica
pig
isol
respiratori
tract
without
evid
patholog
clinic
diseas
howev
b
bronchiseptica
shown
caus
signific
diseas
pig
coinfect
respiratori
virus
includ
iav
inflamm
result
epitheli
immun
cell
chang
follow
iav
infect
suppress
antibacteri
immun
mechan
bacteri
dynam
infect
sever
impact
review
smith
mcculler
robinson
et
al
laiv
vaccin
provid
protect
iav
infect
result
reduct
secondari
bacteri
pneumonia
may
limit
antibiot
usag
howev
intranas
administr
laiv
vaccin
alter
commens
replic
colon
though
chang
limit
upper
respiratori
tract
current
studi
laiv
administr
minim
effect
b
bronchiseptica
densiti
upper
respiratori
tract
appreci
sign
clinic
diseas
follow
laiv
administr
data
shown
day
laiv
administr
day
bb
inocul
signific
differ
amount
bb
nasal
passag
bbnv
bblaiv
pig
howev
could
due
commonli
measur
shift
bb
nasal
colon
around
week
postinocul
uncommon
given
chang
bb
colon
follow
laiv
administr
detect
expect
differ
due
laiv
administr
though
complet
rule
possibl
laiv
administr
alter
overal
bacteri
commun
structur
upper
respiratori
tract
pig
though
addit
studi
need
assess
chang
iav
strain
use
challeng
studi
exact
match
vaccin
antigen
virus
lineag
base
ha
genet
antigen
characterist
distantli
relat
pdmlineag
virus
thu
previous
shown
anticip
replic
challeng
viru
even
laiv
vaccin
group
limit
detect
lower
respiratori
tract
dpi
presenc
lung
lesion
associ
iav
infect
laiv
vaccin
provid
support
iav
replic
lower
respiratori
tract
laivch
pig
though
signific
protect
viru
replic
patholog
signific
increas
cytokin
level
lung
laivch
pig
compar
control
pig
level
laivch
pig
reduc
compar
nvch
pig
provid
support
iav
replic
lower
respiratori
tract
readili
control
laivinduc
immun
overal
b
bronchiseptica
colon
interfer
laiv
immunogen
laiv
vaccin
necessarili
prevent
neg
impact
iavb
bronchiseptica
coinfect
although
b
bronchiseptica
encod
number
figur
alter
cytokin
level
lung
associ
iav
challeng
nonvaccin
pig
regardless
b
bronchiseptica
colon
group
pig
inocul
b
bronchiseptica
bb
laiv
day
subsequ
challeng
ch
heterolog
iav
describ
materi
method
day
postinfect
lung
lavag
collect
level
indic
cytokin
measur
multiplex
elisa
dot
repres
singl
anim
respect
treatment
group
mean
sem
shown
analyz
use
kruskalw
test
dunn
multipl
comparison
posttest
graphpad
prism
group
differ
letter
design
significantli
differ
p
immunomodulatori
protein
presenc
time
laiv
administr
impair
induct
mucos
iga
iav
expect
laiv
induc
product
mucos
iavspecif
cell
shown
speci
impact
b
bronchiseptica
colon
iavspecif
cell
develop
unknown
although
iavspecif
iga
induc
upper
respiratori
tract
pig
follow
laiv
vaccin
b
bronchiseptica
colon
unabl
provid
full
protect
upon
iav
challeng
face
b
bronchiseptica
infect
thu
laiv
vaccin
base
immun
could
protect
neg
interact
occur
iavb
bronchiseptica
coinfect
b
bronchiseptica
sophist
environment
sens
system
bvg
locu
drive
express
numer
virul
factor
includ
uniqu
regulatori
system
control
express
lower
respiratori
tract
minim
patholog
lung
bbonli
pig
bbnvnch
lesion
present
characterist
chronic
b
bronchiseptica
infect
suggest
virul
gene
express
long
initi
b
bronchiseptica
inocul
minim
howev
environment
chang
respiratori
tract
associ
iav
infect
epitheli
damag
andor
alter
abund
solubl
immun
mediat
cytokin
defensin
leakag
serum
protein
airway
may
subsequ
alter
b
bronchiseptica
gene
express
cytotox
factor
produc
bordetella
exposur
albumin
enhanc
product
adenyl
cyclas
toxin
act
act
disrupt
bronchial
epitheli
integr
enhanc
express
b
bronchiseptica
virul
factor
like
contribut
appear
lesion
associ
acut
b
bronchiseptica
infect
limit
replic
challeng
viru
laiv
vaccin
also
colon
b
bronchiseptica
bblaivch
appear
enough
incit
pulmonari
lesion
commonli
associ
acut
b
bronchiseptica
infect
lesion
characterist
associ
acut
b
bronchiseptica
infect
note
bbnvch
bblaivch
group
bbnvnch
group
patholog
chang
due
increas
bacteri
burden
figur
ascrib
patholog
interact
commens
organ
follow
iav
infect
signific
increas
proinflammatori
cytokin
level
recent
b
bronchiseptica
gene
express
vivo
evalu
futur
work
aim
identifi
factor
alter
gene
express
may
provid
insight
mechan
b
bronchiseptica
play
role
secondari
diseas
mucos
cellmedi
immun
cmi
respons
play
role
iav
crossprotect
though
directli
assess
current
studi
b
bronchiseptica
may
alter
induct
cellmedi
immun
lung
laiv
vaccin
pig
though
unlik
given
iavspecif
iga
produc
class
switch
iga
requir
cell
help
histolog
chang
lung
pig
laivch
bblaivch
group
nvch
group
consist
peribronchiolar
lymphocyt
cuf
bronchusassoci
lymphoid
tissu
balt
indic
laiv
like
induc
cmi
respons
lung
regardless
b
bronchiseptica
colon
chang
respiratori
tract
associ
iavb
bronchiseptica
coinfect
regardless
vaccin
statu
may
hinder
immuneprotect
possibl
vaccin
challeng
antigen
close
relat
laiv
vaccin
provid
steril
immun
challeng
would
induct
acut
bordetellosi
bblaivch
group
though
investig
necessari
test
hypothesi
overal
laiv
administr
provid
signific
protect
distantli
relat
strain
iav
substanti
decreas
replic
viru
respiratori
tract
thu
data
present
negat
efficaci
laiv
vaccin
instead
indic
control
b
bronchiseptica
colon
swine
could
limit
neg
interact
iav
bordetella
swine
health
studi
carri
accord
recommend
usdaarsn
anim
diseas
center
anim
care
use
committe
protocol
approv
committe
